Bookmark and Share
BioAssay: AID 435031

SAR analysis of compounds that inhibit Human Immunodeficiency Virus Fusion, cytoxicity assay

The fusion-active conformation of the envelope protein gp41 of HIV-1 consists of an N-terminal trimeric a-helical coiled coil domain, and three anti-parallel C-terminal helices which fold down the grooves of the coiled coil to form a six-helix bundle. Disruption of the six-helix bundle is considered to be a key component of an effective non-peptide fusion inhibitor. This structure forms as a more ..
_
   
 Tested Compounds
 Tested Compounds
All(40)
 
 
Active(7)
 
 
Inactive(33)
 
 
 Tested Substances
 Tested Substances
All(40)
 
 
Active(7)
 
 
Inactive(33)
 
 
 Related BioAssays
 Related BioAssays
AID: 435031
Data Source: Burnham Center for Chemical Genomics (BCCG-A388-GP41-Inhibitors-Cytotox-DryPowder)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2010-07-01
Hold-until Date: 2011-06-30
Modify Date: 2011-06-30

Data Table ( Complete ):           Active    All
BioActive Compounds: 7
Depositor Specified Assays
AIDNameTypeComment
1986uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.confirmatory
1991Summary assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.summary
434967SAR analysis of compounds that inhibit Human Immunodeficiency Virus Fusion.confirmatory
Description:
Data Source: Burnham Center for Chemical Genomics (BCCG)
Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)
Network: NIH Molecular Libraries Production Centers Network (MLPCN)
Grant Number: 1R21NS059403-01
Assay Provider: Dr. Miriam Gochin, Touro University-California, Vallejo, CA

The fusion-active conformation of the envelope protein gp41 of HIV-1 consists of an N-terminal trimeric a-helical coiled coil domain, and three anti-parallel C-terminal helices which fold down the grooves of the coiled coil to form a six-helix bundle. Disruption of the six-helix bundle is considered to be a key component of an effective non-peptide fusion inhibitor. This structure forms as a result of a conformational change in gp41, triggered by gp120 and co-receptor binding to host cell receptors. Prevention of six-helix bundle formation has been recognized as an important mechanism for viral fusion inhibition

This confirmatory, concentration-response assay has been developed and performed to confirm the hits originally identified in "uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors" (AID1986) and to study the structure-cytotoxicity relationship of analogs of the confirmed hits. Compounds are either acquired from commercial sources or synthesized internally.
Protocol
Cell-cell fusion was measured following a published procedure(1), and using cell lines obtained from the NIH Research and Reference Reagents Program. TZM-bl cells expressing CD4, CCR5 and CXCR4(2), and containing an integrated reporter gene for firefly luciferase under control of HIV-1 LTR(3) were used as target cells. They were grown overnight in 96 well plates in DMEM supplemented with 10% FBS, using 25,000 cells per well. The following day, the medium was exchanged with 50 ul reduced serum medium (Gibco - Invitrogen, USA), and 1 ul of compound was added to each well, using 6 serial dilutions to obtain dose response curves. HL2/3 effector cells which produce HIV-1 HXB2 Env, Tat and Rev(4) were added in reduced serum medium, using 50,000 cells per well, to a total well volume of 100 ul. After 6 hours incubation, cell death was measured using Cytotox Glo (Promega, WI, USA). Controls containing 1ul DMSO with and without HL2/3 cells were measured for each compound, and experiments were performed in duplicate.

References:
1. Wexler-Cohen, Y. Shai, Y. Faseb J 2007, 21, 3677.
2. Platt, E. J. Wehrly, K. Kuhmann, S. E. Chesebro, B. Kabat, D. J Virol 1998, 72, 2855.
3. Wei, X. Decker, J. M. Liu, H. Zhang, Z. Arani, R. B. Kilby, J. M. Saag, M. S. Wu, X. Shaw, G. M. Kappes, J. C. Antimicrob Agents Chemother 2002, 46, 1896.
4. Ciminale, V. Felber, B. K. Campbell, M. Pavlakis, G. N. AIDS Res Hum Retroviruses 1990, 6, 1281.
Comment
Compounds with a demonstrated CC50 < 100 uM are defined as actives in this assay and are considered to be cytotoxic.

To simplify the distinction between the inactives of the primary screen and of the confirmatory screening stage, the Tiered Activity Scoring System was developed and implemented. Its utilization for the assay is described below.

Activity Scoring
Activity scoring rules were devised to take into consideration compound efficacy, its potential interference with the assay and the screening stage that the data was obtained. Details of the Scoring System will be published elsewhere. Briefly, the outline of the scoring system utilized for the assay is as follows:
1) First tier (0-40 range) is reserved for primary screening data and is not applicable in this assay.
2) Second tier (41-80 range) is reserved for dose-response confirmation data and is not applicable in this assay
3) Third tier (81-100 range) is reserved for resynthesized true positives and their analogues
a. Inactive compounds of the confirmatory stage are assigned a score value equal 41.
b. The score is linearly correlated with a compound potency.
c. The scoring equation is
Score = 82 + 3*(pCC50 - 3)
where pCC50 is a negative log(10) of the CC50 value expressed in mole/L concentration units. This equation results in the Score values above 85 for compounds that are cytotoxic. Compounds that are inactive in the assay are likely to have low cytotoxicity and will generally have lower Score values.
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1CC50_QualifierThis qualifier is to be used with the next TID, CC50. If qualifier is "=", the CC50 result equals the value in that column. If the qualifier is ">", the CC50 result is greater than that value. If the qualifier is "<", the CC50 result is smaller than that valueString
2CC50*CC50 value determined using sigmoidal dose response equationFloatμM
3Luminescence at 0.41 uM (0.41μM**)% Average luminescence at a given concentrationFloat
4Luminescence at 1.23 uM (1.23μM**)% Average luminescence at a given concentrationFloat
5Luminescence at 3.70 uM (3.7μM**)% Average luminescence at a given concentrationFloat
6Luminescence at 11.11 uM (11.11μM**)% Average luminescence at a given concentrationFloat
7Luminescence at 33.33 uM (33.33μM**)% Average luminescence at a given concentrationFloat
8Luminescence at 100 uM (100μM**)% Average luminescence at a given concentrationFloat

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: 1R21NS059403-01

Data Table (Concise)
PageFrom: